Table 1.

Association of TOP2A and ERBB2 gene expression with breast cancer specific metastasis-free survival in patients with node-negative breast cancer

A. Multivariate Cox analysis of TOP2A gene expression in 496 node-negative breast cancer samples. The cohort (n = 496) is a combination of the Transbig (n = 302) and the Mainz (n = 194) subcohorts
Prognostic factorsPHR (95% CI)
Age (<50 vs ≥50 y)0.4321.166 (0.795-1.710)
pT stage (≤2 cm vs >2 cm)0.4721.113 (0.832-1.489)
Histologic grade (Grade 3 vs grade 1 and 2)0.0661.503 (0.973-2.320)
Hormone receptor status* (ER or PR; negative vs. positive)0.5701.144 (0.719-1.820)
ERBB2 status (positive vs negative)0.5171.183 (0.711-1.967)
TOP2A RNA level<0.0011.356 (1.149-1.599)
B. Association of TOP2A gene expression with metastasis-free survival in 782 patients with node-negative breast cancer. Analysis was done separately in ER-positive versus ER-negative, ERBB2-positive versus ERBB2-negative, and in triple-negative versus non-triple-negative tumors (triple-negative “positive” means that ER, PR, and ERBB2 are negative, whereas triple-negative “negative” comprises all other patients)
VariablePositiveNegative
P (n)HR (95% CI)P (n)HR (95% CI)
ER<0.001 (583)1.591 (1.403-1.806)0.889 (198)0.889 (0.793-1.222)
ERBB20.687 (118)0.951 (0.744-1.215)<0.001 (664)1.560 (1.373-1.772)
Triple negative0.921 (144)1.014 (0.776-1.324)<0.001 (637)1.453 (1.298-1.625)
C. Association of ERBB2 gene expression with metastasis-free survival in 782 patients with node-negative breast cancer. Analysis was done separately in ER-positive versus ER-negative, Top2A low versus high (using the median as a cut point), and in triple-negative versus non-triple-negative tumors (triple negative “positive” means that ER, PR, and ERBB2 are negative, triple negative “negative” comprises all other patients)
VariablePositiveNegative
P (n)HR (95% CI)P (n)HR (95% CI)
ER0.014 (583)1.708 (1.115-2.616)0.267 (198)0.727 (0.414-1.277)
Top2A (high vs low)0.451 (391)0.852 (0.561-1.293)0.015 (391)2.041 (1.146-3.637)
Triple negative0.515 (144)0.048 (0.000-446.7)0.042 (637)1.435 (1.012-2.035)

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.

  • *The hormone receptor status is positive as soon as one of both, the estrogen (ER) or the progesterone receptor status (PR), is positive.